| 今开：6.02 | 昨收：6.01 |
| 最高：6.16 | 最低：5.945 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：5.75592644E8 |
Cogent Biosciences(COGT)02-15 05:15
$Cogent Biosciences(COGT)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-24-001689 Act: 34 Size: 81 KB 网页链接查看全文
Cogent Biosciences(COGT)02-26 21:35
$Cogent Biosciences(COGT)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-019754 Act: 34 Size: 431 KB 网页链接查看全文
Cogent Biosciences(COGT)04-13 04:35
$Cogent Biosciences(COGT)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094760 Act: 34 Size: 728 KB 网页链接查看全文
Cogent Biosciences(COGT)02-15 09:35
$Cogent Biosciences(COGT)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-024207 Act: 34 Size: 258 KB 网页链接查看全文
Cogent Biosciences(COGT)02-17 07:45
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-016610 Size: 9 KB 网页链接查看全文
Cogent Biosciences(COGT)02-06 05:45
$Cogent Biosciences(COGT)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-000675 Act: 34 Size: 121 KB 网页链接查看全文
Cogent Biosciences(COGT)02-26 22:25
$Cogent Biosciences(COGT)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-019770 Act: 34 Size: 16 MB 网页链接查看全文
美股滚雪球02-27 09:57
$Cogent Biosciences(COGT)$ 最近的一次医学会议上，bezuclastinib治疗系统性肥大细胞增多症的1b期数据并不比目前批准的治疗更好。$蓝图医药(BPMC)$ $恒瑞医药(SH600276)$查看全文
Cogent Biosciences(COGT)03-22 20:35
$Cogent Biosciences(COGT)$ 8-K Current report, items 3.02, 5.03, and 9.01 Accession Number: 0001193125-24-074628 Act: 34 Size: 224 KB 网页链接查看全文
Cogent Biosciences(COGT)04-02 06:25
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-039588 Size: 13 KB 网页链接查看全文
Cogent Biosciences(COGT)宣布已开始承销公开发行1.25亿美元的普通股。Cogent打算将此次发行的净收益用于与bezuclastinib和其他候选产品相关的开发、监管和商业准备活动，以及营运资金和一般公司用途。Jefferies、Piper Sandler& Co.和Gugge... 网页链接
$Cogent Biosciences(COGT)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-107128 Act: 34 Size: 142 KB 网页链接
$Cogent Biosciences(COGT)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-107137 Act: 34 Size: 3 MB 网页链接
$Cogent Biosciences(COGT)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-107124 Act: 34 Size: 728 KB 网页链接
$Cogent Biosciences(COGT)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094760 Act: 34 Size: 728 KB 网页链接
$Cogent Biosciences(COGT)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000926 Act: 33 Size: 1 KB 网页链接
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040496 Size: 5 KB 网页链接
$Cogent Biosciences(COGT)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-083703 Act: 34 Size: 72 KB 网页链接
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-039588 Size: 13 KB 网页链接
$Cogent Biosciences(COGT)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-24-082065 Act: 33 Size: 382 KB 网页链接
$Cogent Biosciences(COGT)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-078864 Act: 34 Size: 73 KB 网页链接